BioAtla (BCAB) Enterprise Value (2020 - 2026)
BioAtla (BCAB) posted quarterly Enterprise Value of -$2.0 million for Q1 2026, up 93.94% year-over-year from -$1.0 million in Q1 2025, and up 72.45% quarter-over-quarter from -$7.1 million in Q4 2025.
BioAtla (BCAB) Enterprise Value (2020 - 2026) Analysis & Trends
BioAtla's Enterprise Value history runs 7 years deep, the most recent figure standing at -$2.0 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 93.94% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$2.0 million (up 93.94% YoY), while the FY2025 annual figure was -$7.1 million, up 85.49% from the prior year.
- Enterprise Value for Q1 2026 stood at -$2.0 million, up from -$7.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.0 million in Q1 2026, with the low at -$219.4 million in Q1 2022.
- The 5-year median for Enterprise Value is -$71.1 million (2024), against an average of -$95.6 million.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value advanced 0.8% in 2022, then surged 93.94% in 2026.
- BioAtla's Enterprise Value stood at -$178.1 million in 2022, then jumped by 37.42% to -$111.5 million in 2023, then surged by 56.0% to -$49.0 million in 2024, then jumped by 85.49% to -$7.1 million in 2025, then jumped by 72.45% to -$2.0 million in 2026.
- Business Quant data shows BCAB's Enterprise Value at -$2.0 million in Q1 2026, -$7.1 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | -1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.54 Mn |
| Mar 31, 2026 | -1.96 Mn |
| Dec 31, 2025 | -7.12 Mn |
| Sep 30, 2025 | -8.32 Mn |
| Jun 30, 2025 | -18.21 Mn |
| Mar 31, 2025 | -32.36 Mn |
| Dec 31, 2024 | -49.05 Mn |
| Sep 30, 2024 | -56.52 Mn |
| Jun 30, 2024 | -61.66 Mn |
| Mar 31, 2024 | -80.63 Mn |
| Dec 31, 2023 | -111.47 Mn |
| Sep 30, 2023 | -141.28 Mn |
| Jun 30, 2023 | -168.69 Mn |
| Mar 31, 2023 | -192.69 Mn |
| Sep 30, 2022 | -178.12 Mn |
| Jun 30, 2022 | -202.29 Mn |
| Mar 31, 2022 | -219.43 Mn |
| Dec 31, 2021 | -244.98 Mn |
| Sep 30, 2021 | -269.93 Mn |
| Jun 30, 2021 | -207.61 Mn |